Is Mycobacterium tuberculosis carcinogenic to humans?

Significance of extracellular vesicles in orchestration of immune responses in Mycobacterium tuberculosis infection

Mycobacterium tuberculosis (M.tb), the causative agent of Tuberculosis, is an intracellular bacterium well known for its ability to subvert host energy and metabolic pathways to maintain its intracellular survival. For this purpose, the bacteria utilize various mechanisms of which extracellular vehicles (EVs) related mechanisms attracted more attention. EVs are nanosized particles that are released by almost all cell types containing active biomolecules from the cell of origin and can target bioactive pathways in the recipient cells upon uptake. It is hypothesized that M.tb dictates the processes of host EV biogenesis pathways, selectively incorporating its molecules into the host EV to direct immune responses in its favor. During infection with Mtb, both mycobacteria and host cells release EVs. The composition of these EVs varies over time, influenced by the physiological and nutritional state of the host environment. Additionally, different EV populations contribute differently to the pathogenesis of disease at various stages of illness participating in a complex interplay between host cells and pathogens. These interactions ultimately influence immune responses and disease outcomes. However, the precise mechanisms and roles of EVs in pathogenicity and disease outcomes remain to be fully elucidated. In this review, we explored the properties and function of EVs in the context of M.tb infection within the host microenvironment and discussed their capacity as a novel therapeutic strategy to combat tuberculosis.

Can Mycobacterium tuberculosis infection lead to cancer? Call for a paradigm shift in understanding TB and cancer

Infections are known to cause tumours though more attributed to viruses. Strong epidemiological links suggest association between bacterial infections and cancers as exemplified by Helicobacter pylori and Salmonella spp. Infection with Mycobacterium tuberculosis (M. tb), the etiological agent of tuberculosis (TB), has been reported to predispose patients to lung cancers and possibly in other organs as well. While this etiopathogenesis warrant inclusion of M. tb in IARC's (International Agency for Research on Cancer) classified carcinogenic agents, the lack of well-defined literature and direct experimental studies have barred the research community from accepting the role of M. tb as a carcinogen. The background research, case studies, and experimental data extensively reviewed in Roy et al., 2021; provoke the debate for elucidating carcinogenic properties of M. tb. Moreover, proper, timely and correct diagnosis of both diseases (which often mimic each other) will save millions of lives that are misdiagnosed. In addition, use of Anti Tubercular therapy (ATT) in misdiagnosed non-TB patients contributes to drug resistance in population thereby severely impacting TB disease control measures. Research in this arena can further aid in saving billions of dollars by preventing the superfluous use of cancer drugs. In order to achieve these goals, it is imperative to identify the underlying mechanism of M. tb infection acting as major risk factor for cancer.

The relationship between previous pulmonary tuberculosis and risk of lung cancer in the future

Various investigations have expanded the views that tuberculosis is an important risk factor for lung cancer occurrence. Lung cancer originates from chronic inflammation and infection. It is becoming clearer that Mycobacterium tuberculosis (M.tb) in tuberculosis patients meticulously schemes multiple mechanisms to induce tumor formation and is indispensable to participate in the occurrence of lung cancer. In addition, some additional factors such as age, sex and smoking, accelerate the development of lung cancer after Mycobacterium tuberculosis infection. The clarification of these insights is fostering new diagnoses and therapeutic approaches to prevention of the patients developing from tuberculosis into lung cancer.

The Role of Chest CT Radiomics in Diagnosis of Lung Cancer or Tuberculosis: A Pilot Study

In many low-income countries, the poor availability of lung biopsy leads to delayed diagnosis of lung cancer (LC), which can appear radiologically similar to tuberculosis (TB). To assess the ability of CT Radiomics in differentiating between TB and LC, and to evaluate the potential predictive role of clinical parameters, from March 2020 to September 2021, patients with histological diagnosis of TB or LC underwent chest CT evaluation and were retrospectively enrolled. Exclusion criteria were: availability of only enhanced CT scans, previous lung surgery and significant CT motion artefacts. After manual 3D segmentation of enhanced CT, two radiologists, in consensus, extracted and compared radiomics features (T-test or Mann−Whitney), and they tested their performance, in differentiating LC from TB, via Receiver operating characteristic (ROC) curves. Forty patients (28 LC and 12 TB) were finally enrolled, and 31 were male, with a mean age of 59 ± 13 years. Significant differences were found in normal WBC count (p < 0.019) and age (p < 0.001), in favor of the LC group (89% vs. 58%) and with an older population in LC group, respectively. Significant differences were found in 16/107 radiomic features (all p < 0.05). LargeDependenceEmphasis and LargeAreaLowGrayLevelEmphasis showed the best performance in discriminating LC from TB, (AUC: 0.92, sensitivity: 85.7%, specificity: 91.7%, p < 0.0001; AUC: 0.92, sensitivity: 75%, specificity: 100%, p < 0.0001, respectively). Radiomics may be a non-invasive imaging tool in many poor nations, for differentiating LC from TB, with a pivotal role in improving oncological patients’ management; however, future prospective studies will be necessary to validate these initial findings.